Aurobindo Pharma receives tentative approval for its New Drug Application (NDA) Nevirapine Tablets for Oral Suspension 50mg

25th February 2010

Aurobindo Pharma Limited is pleased to announce that it has received the tentative approval to manufacture and market Nevirapine Tablets for Oral Suspension 50mg (NDA) from the US Food & Drug Administration (USFDA).

The New Drug Application (NDA) 22-299 provides for the use of Nevirapine Tablets for Oral Suspension 50mg in combination with other antiretrovirals agents and is indicated for the treatment of HIV infections.

Aurobindo has a total of 113 ANDA approvals (84 Final approvals and 29 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com